»ó´Ü¿©¹é
HOME ´º½º
½Å¾à°³¹ß¿¬±¸Á¶ÇÕ, 40°³»ç 77¸í ±¸¼º ±â¼ú°Å·¡À§ Ãâ¹ü

Çѱ¹½Å¾à°³¹ß¿¬±¸Á¶ÇÕÀº ¿À´Â 28ÀÏ ¿ÀÈÄ 1½Ã20ºÐ ¼­¿ï »ïÁ¤È£ÅÚ Á¦¶ó´½È¦¿¡¼­ Çѱ¹½Å¾à°³¹ß¿¬±¸Á¶ÇÕ »êÇÏ Á¦¾à»ê¾÷±â¼ú°Å·¡¼¾ÅÍ(PTBC; PharmaTech Business Center) 17Â÷³âµµ ±â¼ú°Å·¡À§¿ø(TBC) Ãâ¹ü½Ä°ú ±â¼ú»ç¾÷È­ ¼³¸íȸ¸¦ °³ÃÖÇÏ°í 40°³»ç 77¸íÀ¸·Î ±¸¼ºµÈ ±â¼ú°Å·¡À§¿ø À§Ã˽ÄÀ» °³ÃÖÇÑ´Ù.
 
Çѱ¹½Å¾à°³¹ß¿¬±¸Á¶ÇÕ Á¦¾à»ê¾÷±â¼ú°Å·¡¼¾ÅÍ´Â Áö³­ 2000³âµµ¿¡ ¿ì¸®³ª¶ó¿¡¼­ ÃÖÃÊ·Î ¼³¸³µÈ ¹Î°£ ±â¼ú°Å·¡±â±¸·Î¼­ ȸ¿ø»çÀÇ ±Û·Î¹ú Çõ½Å¿ª·®°­È­¸¦ À§ÇØ ±¹³»¿Ü À¯¸Á±â¼ú ¹ß±¼ ¹× ±â¼úÀÌÀü Á¤º¸ Á¦°øÀ» À§ÇÑ ºñ°ø°³ ȸÀÇ/»ç¾÷¼³¸íȸ °³ÃÖ, ±â¼ú¸¶ÄÉÆà Àü¹®Àη ¾ç¼º, ±¹³»¿Ü ±â¼ú°Å·¡ Çù·Â »ç¾÷ ÃßÁø µî ´Ù°¢ÀûÀÎ È°µ¿À» ÆîÄ¡°í ÀÖ´Ù.
 
Áö³­ÇØ¿¡´Â ±¹³»¿Ü 63°³ ±â°üÀ¸·ÎºÎÅÍ 340°³ À¯¸Á ¾ÆÀÌÅÛÀ» ¹ß±¼ ¹× ½ÉÀÇÇÏ¿´°í, ÀÎÅͺñÁî ¹ÙÀÌ¿ÀÆÄÆ®³Ê¸µ&ÅõÀÚÆ÷·³°ú °°Àº ´ë±Ô¸ð ±â¼úÀÌÀüÀÇ ÀåÀ» ¸¶·ÃÇÏ´Â µî ȸ¿ø»çÀÇ ¿ÀÇÂÀ̳뺣ÀÌ¼Ç È°µ¿À» Àû±Ø Áö¿øÇß´Ù.
 
ÇÑÆí, À̳¯ Ãâ¹ü½Ä¿¡¼­´Â Çѱ¹´ëÇбâ¼úÀÌÀüÇùȸ ÀÌâÁØ Àü·«±âȹÆÀÀå°ú Çѱ¹¿¬±¸¼Ò±â¼úÀÌÀüÇùȸ ÀÌÀÎÈñ »ç¹«±¹ÀåÀÌ ‘Á¦¾à»ê¾÷·¹ÙÀÌ¿À±â¼úºÐ¾ß »êÇп¬ Çù·Â ÃßÁø °èȹ’¿¡ ´ëÇؼ­ ¹ßÇ¥ÇÒ ¿¹Á¤À̸ç, ÀÌ¾î ±â¼ú»ç¾÷È­ ¼³¸íȸ¿¡¼­´Â µ¿±¹´ë¾à´ë ±è¿µ¿ì ±³¼ö°¡ `»õ·Î¿î Ç×±ÕÀÛ¿ë ±âÀüÀ» °®´Â ÀÌÁß ½ºÅ×ÀÌÇÃÈ­µÈ ÆéŸÀ̵å`, Áß¾Ó´ë¾à´ë ¹Î°æÈÆ ±³¼ö°¡ `4¼¼´ë EGFR TKIÀÇ °³¹ß(Discovery of 4th generation EGFR Tyrosine kinase inhibitors)`¿¡ ´ëÇÑ ±â¼úÀ» ¹ßÇ¥ÇÑ´Ù.
 

±èÁø¼· ±âÀÚ  jin2001kim@pharmstock.co.kr

<ÀúÀÛ±ÇÀÚ © ÆʽºÅ¹, ¹«´Ü ÀüÀç ¹× Àç¹èÆ÷ ±ÝÁö>

±èÁø¼· ±âÀÚÀÇ ´Ù¸¥±â»ç º¸±â
iconÀαâ±â»ç
±â»ç ´ñ±Û 0°³
Àüüº¸±â
ù¹ø° ´ñ±ÛÀ» ³²°ÜÁÖ¼¼¿ä.
Back to Top